MTOR and colorectal carcinoma: Mutation of K-RAS occurs in 30–50% of CRC cells and K-RAS mutations can lead to the aberrant activation of several oncogenic signaling pathways including the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) signaling pathway [13,14].